[In vitro activity of voriconazole and other antifungal agents against clinical isolates of 138 Candida spp]. / Attivita in vitro del voriconazolo e di altri agenti antimicotici nei confronti di 138 isolati clinici di Candida spp.
Infez Med
; 17(1): 24-7, 2009 Mar.
Article
in It
| MEDLINE
| ID: mdl-19359821
ABSTRACT
Voriconazole is used for treating invasive Aspergillosis, Fusarium and Scedosporium infections as well as resistant candidiasis. It is referred to as a second generation triazole. The purpose of this study was to evaluate the concordance of the results of antifungal voriconazole susceptibility tests for yeast isolates, comparing the Sensititre YeastOne method, Atb Fungus 3 and Etest. In all, 138 yeast isolates (42 C. tropicalis, 36 C. glabrata, 14 C. albicans, 8 C. famata, 6 C. parapsilosis, 4 C. dubliniensis, 3 C. krusei, 3 C. lusitaniae, 2 C. zeylanoides, 20 Candida spp.) were tested for susceptibility to amphotericin B, flucytosine, fluconazole , itraconazole and voriconazole with Atb Fungus 3 method. The concordance between the Sensititre YeastOne method, Atm Fungus 3 and Etest for voriconazole was high (90%).
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pyrimidines
/
Triazoles
/
Candida
/
Antifungal Agents
Limits:
Humans
Language:
It
Journal:
Infez Med
Year:
2009
Document type:
Article